Effect of single agent vemurafenib in BRAF mutated NSCLC cell lines. Using a long-term growth assay vemurafenib was found to be effective in BRAF-V600E mutated HCC364 cells and not in non-V600E BRAF mutated H1755 cells (Fig. 2A). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.